Table III.
Univariate prognostic analysis of overall survival
| Univariate analysis | ||
|---|---|---|
|
| ||
| 2-year OS rate | Log-rank p-value | |
| Male | 16.9% | |
| Female | 37.0% | 0.10 |
| Age | ||
| < 15 years | 23.8% | |
| ≥15 years | 17.5% | 0.66 |
| Stage (St. Judes) | ||
| I / II | 40.0% | |
| III | 22.8% | |
| IV / ALL | 20.2% | 0.45 |
| Prognosis group | ||
| Group A | 50.0% | |
| Group B | 25.1% | |
| Group C | 16.7% | 0.25 |
| Histology | ||
| Burkitt / Burkitt like | 19.1% | |
| DLBCL (not PMBL) | 35.1% | |
| PMBL | 28.6% | |
| Other NOS | 28.6% | 0.26 |
| Primary site | ||
| Thorax | 26.9% | |
| Abdomen/Retroperitoneal | 20.7% | |
| B-ALL | 7.1% | |
| Other | 38.9% | 0.058 |
| LDH | ||
| < 2 NL | 41.8% | |
| ≥2 NL | 14.9% | 0.0004 |
| Bone Marrow | ||
| Not involved | 23.4% | |
| Involved | 20.2% | 0.21 |
| Central Nervous System | ||
| Not involved | 24.1% | |
| Involved | 16.7% | 0.27 |
| Time to failure | ||
| ≤ 6 months | 15.4% | |
| > 6 months | 34.5% | 0.002 |
| Type of failure | ||
| No CR (refractory) | 10.7% | |
| Failure after CR | 26.8% | 0.047 |
| Failure at initial localisation | ||
| No | 24.8% | |
| Yes | 20.7% | 0.84 |
| Failure in bone marrow | ||
| No | 26.0% | |
| Yes | 11.5% | 0.003 |
| Failure in CNS | ||
| No | 23.7% | |
| Yes | 19.4% | 0.77 |
| Failure in other sites | ||
| No | 21.9% | |
| Yes | 23.0% | 0.63 |
| Number of sites of failure | ||
| 1 | 27.2% | |
| >1 | 15.0% | 0.14 |
B-ALL, B cell acute lymphoblastic lymphoma; CI, confidence interval; CNS, central nervous system; CR, complete response; DLBCL, diffuse large B cell lymphoma; HR, hazard ratio; LDH, lactate dehydrogenase; NL, normal limit; NOS, not otherwise specified; OS, overall survival; PMBL, primary mediastinal large B cell lymphoma.